Novo Nordisk announced Monday that in two closely watched studies, an oral version of semaglutide — the active ingredient in weight loss drugs — failed to help slow the progression of Alzheimer’s.
Dr. Terry Dubrow and Heather Dubrow explain one of the NSFW side effects related to men who take Ozempic or other semaglutide ...
Novo Nordisk GLP-1 fails to slow Alzheimer's in phase 3 trials involving 3,808 adults with mild cognitive impairment or dementia.
In two Phase 3 trials, researchers tested an oral form of semaglutide in more than 3,800 adults with Alzheimer’s who were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback